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Evaluation of plasma levels of tumour necrosis factor
alpha and interleukin-6 as rejection markers in a
cohort of 142 heart-grafted patients followed by
endomyocardial biopsy
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The rejection reaction after cell or organ transplantation
has to be detected as early as possible in order to conduct
optimal immunosuppressive treatment. Among the numer-
ous events leading to rejection, cytokine production, espe-
cially of tumour necrosis factor alpha, is particularly
important. Interleukin-6 and tumour necrosis factor alpha
were investigated in 142 heart-grafted patients in order to
define an early peripheral non-invasive marker of an acute
rejection that could fit well with myocardial biopsy results.
Cytokines were immunoenzymatically measured in blood
specimens collected on the day of the endomyocardial
biopsy. The values were compared to the grade of heart
graft rejection established according to pathological cri-
teria. Plasma interleukin-6 and especially tumour necrosis
factor alpha determined on the day of the rejection diag-
nosis were significantly increased in the patient sample with
moderate or severe rejection when compared with mean
values of interleukin-6 and tumour necrosis factor alpha in
the patient sample without rejection or with mild rejection
(/
>=004 and 0001 respectively). Because high levels of
tumour necrosis factor alpha may appear before histologi-
cal signs, this biological marker could be useful in the
follow-up of heart-grafted patients.
(Eur Heart J 1997; 18: 1024-1029)
Key Words: Cardiac transplantation, heart-graft rejection,
tumour necrosis factor alpha, interleukin-6.
Introduction
The immunological mechanism of rejection of a trans-
planted heart begins with the recognition of graft anti-
gens and the recruitment of cytotoxic T lymphocytes.
Then, together with the release of inflammatory cyto-
kines (interferon-)', tumour necrosis factor), the pro-
liferation and differentiation of T and B lymphocytes
occur, leading to macrophage activation and the release
of tumour necrosis factor alpha and beta, interleukin-1
and other messengers. Finally, graft lysis occurs, as a
result of the direct action of macrophages, T cells, K.
cells and of cytotoxic effects mediated by cytokines and
other molecules. These mediators might not only be
biological markers of rejection but also accurate
parameters demonstrating the effectiveness of new
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immunosuppressive treatments specifically directed
towards anti-allograft immunity'
1'.
Several biological actions are assigned to
interleukin-6, particularly regarding immune response,
inflammatory reaction and, recently, graft rejection. The
latter role has not yet been fully assessed. Studies in vitro
have shown that interleukin-6 is involved in T-cell
proliferation and activation, in the induction of cyto-
toxic T lymphocyte clonal expansion
121 and in B-cell
differentiation with the development of alloantibodies
[31.
Several human clinical studies have described a large
increase in serum interleukin-6 levels after organ trans-
plantation, with a subsequent decrease to normal range
within 2-3 weeks in uncomplicated cases. Serum
interleukin-6 levels substantially increased a few days
before or during the episodes of clinical rejection'
41.
The pro-inflammatory nature of tumour necrosis
factor can account for its participation in the rejection
mechanism. Tumour necrosis factor is known to regu-
late the immunogenicity of the transplanted tissue by
amplification of class I
[5] and II
[6] human leukocyte
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antigen gene expression. Tumour necrosis factor can
also regulate stimulation of neoantigen expression on
human endothelial cells, which could explain the in-
crease in anti-endothelial cell antibodies in patients
undergoing humoral allograft rejection'
71. Moreover,
tumour necrosis factor amplifies rejection by a direct
cytotoxic effect
181 or via T cell
191 or macrophage'
101
action. Tumour necrosis factor appears to induce the
release of other cytokines and the appearance of many
cytotoxic effector cells. Elevated tissular or plasmatic
levels of tumour necrosis factor alpha were found at
the time of, or a few days before, a clinical diagnosis of
heart rejection
17-
11'
121. These data suggest that increased
plasma tumour necrosis factor levels in cardiac allograft
recipients may be used as a peripheral marker for
predicting severe allograft rejection'
131. Treatment with
anti-tumour necrosis factor antibodies is known to
significantly inhibit cardiac allograft rejection in
animals
1'
4'
151. Measurement of plasma tumour necrosis
factor levels is quite difficult owing to poor correlation
with immunological or inflammatory events, the cyclic
release of tumour necrosis factor from stimulated
immuno-competent cells and tumour necrosis factor
instability in serum and plasma. Thus, continuous
monitoring is required to display the peak level'
161.
Both interleukin-6 and tumour necrosis factor
present the same technical difficulties of measure-
ment'
171. Furthermore, the primary release of pro-
inflammatory cytokines is probably triggered by the
tissue or the organ of interest, but only hyperactivation
of the immune system induces a generalized reaction
with high plasma tumour necrosis factor levels. The use
of serum cytokines in predicting allograft rejection
is under various influences. The nature of these are
the immunosuppressive protocols used by various
transplantation programmes, the occurrence of oppor-
tunistic infections, or the development of ischaemic
myocardiopathy.
Up to now, the diagnosis and grading of rejec-
tion have been mainly based on endomyocardial
biopsy'
181 which is invasive and sometimes difficult to
interpret. An alternative procedure (or at least a
complementary one) involving cytokine evaluation
would be of great benefit for early diagnosis, monitor-
ing of cardiac allograft rejection and modulation of
immunosuppressive treatment.
This paper aims at studying how interleukin-6
and tumour necrosis factor alpha act as plasmatic
biochemical markers for the occurrence and severity of
allograft rejection, defined according to clinical and
pathological data in a cohort of heart-grafted patients.
Methods
Patients
One hundred and forty-two heart-transplanted patients
(129 males, 13 females), 18 to 67 years old (mean = 51)
were included. The patients presented with end-stage
heart disease and were grafted between August 1986 and
October 1994 in the Cardiologic University Hospital of
Bordeaux. Study A was a 36-month (July 1992-June
1995) clinicobiological and pathological follow-up to
determine plasma tumour necrosis factor alpha and
interleukin-6. Study B comprised 27 of the 142 patients.
They were grafted after July 1992 and had weekly
tumour necrosis factor alpha and interleukin-6 determi-
nations during the early post-transplantation period.
Immunosuppressive therapy
Post-transplantation immunosuppression consisted of
cyclosporine (6-8 mg . kg" ' . day" ' in order to main-
tain plasma levels at 150-200 ng. ml"
1), azathioprine
(2-3 mg . kg"
 l according to white blood cell counts)
and prednisolone (30-50 mg . day"').
Endomyocardial biopsies
These were performed weekly for the first 4 weeks after
transplantation in patients who developed an allograft
rejection, in order to monitor responses to immuno-
suppressive therapy. Thereafter, endomyocardial bi-
opsies were carried out with decreasing frequency. The
grading of allograft rejection, according to the Inter-
national Society for Heart and Lung Transplantation
criteria'
181 was determined after histopathological exami-
nation for four endomyocardial biopsy specimens: grade
0: absent rejection; grade IA: focal mild rejection; grade
IB: diffuse mild rejection; grade II: focal moderate
rejection; grade IIIA: multifocal moderate rejection;
grade IIIB: diffuse moderate rejection; grade IV: severe
rejection. For analysis of our data, we used a simplified
clinicotherapeutic classification: on the one hand, no or
mild rejection (corresponding to grades 0, IA and IB)
and, on the other, moderate or severe rejection (corre-
sponding to grades II, IIIA, IIIB and IV). Table 1 gives
the distribution of the 142 allografted patients investi-
gated (i) according to the criteria of the International
Society for Heart and Lung Transplantation and (ii)
according to our simplified clinicotherapeutic classifi-
cation. No specimen was classified grade IIIB or IV.
Cytokine determinations
Blood samples from cardiac allograft recipients were
collected in sterile EDTA-treated vacuum tubes. After
immediate centrifugation, plasma supernatants were
stored at — 80 °C before analysis. Plasma samples were
analysed using ELISA kits for interleukin-6 (Euro-
genetics, Belgium) and tumour necrosis factor alpha
(Immunotech, France) with specific monoclonal anti-
bodies and labelling systems (biotin-streptavidin for
interleukin-6 and alkaline phosphatase for tumour
necrosis factor alpha). Interpretation of interleukin-6
and tumour necrosis factor alpha values was done by
Eur Heart J, Vol. 18, June 1997
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Table 1
n
Distribution
0
26
18-3
of the 142 allografted patients (in
International Society for Heart and Lung
Transplantation classification
IA
28
19 7
IB II IIIA
32 24 32
22-6 16-8 22-6
IIIB
0
0
number
IV
0
0
and percentage)
Simplified clinicotherapeutic
classification
No or mild rejection
0+IA + IB
86
60-6
Moderate or severe rejection
II + IIIA + IIIB + IV
56
39-4
Table 2 Plasma tumour necrosis factor alpha ( TNF-a) and interleukin-6( IL-6) levels in heart-grafted patient groups
divided into no rejection or mild rejection (NR) and moderate or severe rejection (R)
NR group (n = 86) R group (n = 56)
Mean value Maximum value
(from several specimens (during the follow-up)
of each patient)
Simultaneous value Maximum value
(on the day of rejection (during the follow-up)
diagnosis)
IL-6 (pg. ml"
1)
TNF-a(pg.mr') 110 ±1-7
8-3 ±0-8
- 002 -
28-6 ±5-1 • 005 -» 95-9 ± 340
0 001
231-7 ±49-6
-005-
20-4 ±3-6 ns-» 13-7 ±2-4
0 04
39-8 ±7-9
Variables are expressed as mean and standard error. P values are indicated in italics.
ns = no significant. There is significance when P<005.
reference with our usual normal range (<10pg.ml '
and <20 pg . ml ~ ' respectively).
Statistical analysis included the use of the
Student t-test and the Gauss Z test for comparison of
mean values. The Cox proportional hazards model was
used for analysing patients in the 3-month period after
transplantation. Variables were expressed as mean and
standard error. Results were considered significant when
P was less than 0-05.
Results
In study A, we included 142 patients. Eighty six experi-
enced no or mild rejection (NR group) and 56 moderate
or severe rejection (R group), with repeated tumour
necrosis factor alpha and interleukin-6 determinations.
For each cytokine we defined a maximum level in the
two groups, a mean level in the NR group and a
simultaneous level (i.e. the level on the day of the first
rejection diagnosis) in the R group. Interleukin-6 and
tumour necrosis factor alpha were more raised in the R
group than the NR group (Table 2). There was a
significant difference between maximum values for
interleukin-6 and especially for tumour necrosis factor
alpha (P-004 and F=0001). The significant difference
remained when the mean values of the NR group were
compared with simultaneous levels (/
>=005 and 002 for
interleukin-6 and tumour necrosis factor alpha, respect-
ively). Nevertheless, only for tumour necrosis factor
alpha was the simultaneous level of the R group signifi-
cantly higher (P=005) than the maximum level of the
NR group. The positive predictive value calculated from
plasma tumour necrosis factor alpha higher than
20 pg . ml"' and interleukin-6 higher than 10 pg . ml" '
was 65% for each cytokine; the negative predictive value
was 68% and 71% with tumour necrosis factor alpha
and interleukin-6, respectively. There was no significant
increase in predictive values when tumour necrosis
factor alpha and interleukin-6 were combined. (Positive
predictive value = 68%; negative predictive value=72%).
We noted among the false positive patients: cyto
magalovirus infections, myocardial ischaemia, chronic
active hepatitis and thrombotic complications.
Study B comprised the 27 patients followed-up
weekly for 3 months since the graft day. There were
8 NR and 19 R, and they constituted a patient sample
representative of the 142 patients of study A. The aim
was (i) to compare cytokine evolution profiles between
NR and R groups and (ii) to define a possible predic-
tive value of tumour necrosis factor alpha and/or
interleukin-6 as regards the occurrence of rejection in the
first 3 months after transplantation. Figure 1 shows the
tumour necrosis factor alpha and interleukin-6 profiles
of the two groups. There was no significant difference
for interleukin-6, but tumour necrosis factor alpha
appeared significantly elevated in the 4 first weeks (and
in week 8) after transplantation in the R group. Positive
predictive value and negative predictive value calculated
with tumour necrosis factor alpha and interleukin-6
Eur Heart J, Vol. 18, June 1997
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Figure 1 Comparison between NR (M) and R (•) groups of
weekly plasma levels of tumour necrosis factor alpha (TNF-o)
and interIeukin-6 (IL-6) for 3 months after cardiac transplanta-
tion (in weeks 1, 2, 3, 4, 6, 7, 8, and 11). Not enough data were
available in weeks 5, 9, 10 and 12. Vertical bars correspond to
standard error. Significance (R vs NR) is as follows: *.P=0-05,
f/
)=002, J/>=0002, §/
>=0001.
associated plasma levels (in the same conditions as
before) were, respectively, 90% and 88%, showing an
increased predictive accuracy. Nevertheless, by using the
Cox model with a time-dependent variable, we noted an
absence of significance, meaning that at neither time did
tumour necrosis factor alpha have an influence on
instantaneous moderate or severe rejection risk. In our
sample, the first rejection episode appeared within the
2 months after transplantation, nearly two-thirds of
patients rejecting in weeks 2, 3 or 4 (Fig. 2).
In nine patients who developed several episodes
of moderate or severe rejection, plasma cytokine levels
remained very high (tumour necrosis factor alpha from
100 to more than 1000 pg . ml ~ ' and interleukin-6 from
20 to 100 pg . ml"') for a long time (from 1 month to
1 year).
Discussion
Up to now, many investigations have been carried out
on the role of cytokines in mediating humoral allograft
rejection. Only a few have focused on the use of cytokine
Eur Heart J, Vol. 18, June 1997
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3456789 10
Weeks after transplantation
12
Figure 2 Distribution of patients with moderate or severe
rejection according to time of rejection after transplanta-
tion. Percentages are shown in the columns.
measurements for the biological supervision of heart
graft. Some authors
1'
9 22] showed no correlation of
plasma cytokine levels with grade of allograft rejec-
tion. On the other hand, previous studies reported
rises of interleukin-6
[4'
231 and tumour necrosis factor
alpha'
7'"'
121 in allograft tissue or in peripheral blood,
either at the same time or some days before the appear-
ance of pathological and clinical signs of rejection. Our
data confirm tumour necrosis factor alpha involvement
in moderate or severe allograft rejection episodes. We
agree with the observation that after a recent graft, a
transitory increase in interleukin-6 could be linked with
stress, inflammatory stimulus, 1 severe infection, or
myocardial ischaemia'
241.
The presence of significantly high levels of
tumour necrosis factor alpha only in patients suffering
from moderate or severe heart graft rejection indicates
that tumour necrosis factor alpha could be an interesting
marker of rejection, even if the demonstration of its
predictive value is not definitely provided here.
We noted that, although the majority of patients
with moderate or severe rejection presented with high
levels of tumour necrosis factor alpha, a minority (three
out of 19) had normal or slightly elevated tumour
necrosis factor alpha. A possible explanation could be
inter-individual differences in tumour necrosis factor
alpha gene expression'
251. We undertook studies on the
tumour necrosis factor alpha gene in heart-grafted
patients in order to search for a possible association
between tumour necrosis factor alpha gene variation
and risk for rejection, as expressed by plasma tumour
necrosis factor alpha values.
In conclusion, plasma tumour necrosis factor
alpha determination is important and may be a reliable
marker of cardiac allograft rejection. This can be
checked weekly in the early post-transplantation
follow-up period, then monthly. However, patient
supervision still requires the use of biopsies. Further
investigations, in larger patient cohorts, linking new
plasma cytokine determinations with tumour necrosis
factor alpha are necessary to specify the use of a relevant
cytokine profile in the biological supervision of cardiac
transplantation. To explain differences in cytokine pro-
duction between allografted patients, and in predicting
allograft rejection, further studies are needed. Studies on
tumour necrosis factor alpha polymorphism and cyto-
kine gene expression in endomyocardial biopsy tissue
can contribute to this work.
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